Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|May 11, 2006
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancerF Ciardiello, T Troiani, F Caputo, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 18, 2019
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpressionS Napolitano, N Matrone, A L Muddassir, et al.
British Journal of Cancer|May 10, 2012
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cellsT Troiani, L Vecchione, E Martinelli, et al.
Gastroenterology Research and Practice|July 10, 2018
Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score AnalysisJ Ventriglia, A Petrillo, M Huerta Alváro, et al.
British Journal of Cancer|January 20, 2011
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancerF De Vita, M Orditura, E Martinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trialN Normanno, R Esposito Abate, M Lambiase, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approachE Cioli, G Suarato, R Napolitano, et al.
Cancer Medicine|March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trialsG Martini, D Ciardiello, V Famiglietti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2014
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trialF Ciardiello, N Normanno, E Maiello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2016
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOXF Ciardiello, N Normanno, E Martinelli, et al.
Pageof 5